Gelonghui, April 8, 丨 Li Sheng Pharmaceutical (002393.SZ) announced that recently, Tianjin Lisheng Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” (approval number: 2024B01369, 2024B01370) issued by the State Drug Administration for injectable hydrocortisone sodium (hereinafter referred to as the “drug”) 50mg (according to C21H30O5) and 0.1g (based on C21H30O5).

Indications for injectable hydrocortisone sodium succinate: It is used to rescue critical patients such as toxic infections, anaphylactic shock, severe adrenocortical insufficiency, connective tissue, and severe allergic diseases such as bronchial asthma, and can also be used to prevent and treat acute transplant rejection.